Drug Design Development and Therapy · 2020 · 28 citations · 21 references
Life SciencesNeurosciencePharmacologyApoptosisInflammationNeuropharmacologyAcute Ischemic StrokeBlood-brain Barrier BiologyBlood-brain Barrier DysfunctionCerebrovascular DiseaseNeuroprotectionStrokeApoptosis Of Endothelial CellsBlood-brain Barrier PermeabilityCerebral Ischemia NeuroprotectionIschemia-induced Barrier DisruptionRodent Cerebral IschemiaStroke-associated Barrier DysfunctionVascular Endothelial Growth FactorVascular Endothelial Growth Factor Receptors
INTRODUCTION: Ischemic brain injury due to stroke or other pathologies is a major contributor to disability and mortality worldwide. Upon the occurrence of stroke, neuronal cells undergo apoptosis due to the deprivation of oxygen and nutrients and failure of the blood-brain barrier (BBB). In the moments immediately following a stroke, widespread perfusion resulting from hyperpermeability is accompanied by an acute inflammatory response, which induces neovascularization and often permanent neurological injury. Vascular endothelial growth factor (VEGF) and its receptor VEGF receptor 2 (VEGFR2) have been targeted to suppress cerebral ischemia. Recently, natural products including flavonoids, such as juglanin, have been receiving increasing attention for their impressive physiological effects. METHODS: Twenty mg/kg body weight juglanin was administrated for 3 weeks before inducing middle cerebral artery occlusion (MCAO) in mice. The animal brain infarction volume, neurological deficit score, blood-brain barrier permeability, and the expression of tight junction proteins were evaluated. Endothelial permeability and tight junction protein expression were also assessed in brain microvascular endothelial cells (HMBVECs) exposed to oxygen-glucose deprivation/reperfusion (OGD/R). RESULTS: Juglanin significantly reduced occlusion-induced infarct volume and improved neurological score by suppressing BBB hyperpermeability. Juglanin inhibited both the mRNA and protein expression of VEGF and VEGFR2 and restored the normal expression of occludin and zonula occludens-1 (ZO-1), two important tight junction proteins, in MCAO mice. Meanwhile, the results of in vitro experiments show that the protective effects of juglanin against increased BBB permeability and reduced tight junction functionality are dependent on the VEGF/VEGFR2 signaling pathway, as evidenced by the capacity of exogenous VEGF-A to abolish the effects of juglanin. CONCLUSION: Our findings indicate a potent ability of juglanin to prevent neuronal injury resulting from cerebral ischemia by modulating the VEGF/VEGFR2 signaling pathway. Further research will help elucidate the exact mechanisms behind the protective effects of juglanin.
21
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
Michiru Nishita, Seung‐Yeol Park, Tadashi Nishio et al. · Scientific Reports · 2017 · 16.1K citations · Full text
Evolution of blood-brain-barrier permeability after acute ischemic stroke
Zamir Merali, Kun Huang, David J. Mikulis et al. · PLoS ONE · 2017 · 166 citations · Full text
Medicine, Neurology, Neuroscience +17